Skip to main content
SpringerLink
Log in

Die Rolle der molekularen Bildgebung (PET-CT) in der Diagnostik und Therapie des Prostatakarzinoms

The role of molecular imaging (PET-CT) in the diagnostic and treatment pf prostate cancer

  • themenschwerpunkt
  • Published:
Wiener Medizinische Wochenschrift Aims and scope Submit manuscript

Zusammenfassung

In den Industrieländern stellt das Prostatakarzinom die häufigste Tumorart des Mannes dar. Beim biochemischen Rezidiv nach Prostatakarzinom stellt die molekulare Bildgebung mittels PET-CT bzw. PET-MRT ein vielversprechendes Verfahren bei der Suche nach einem Lokalrezidiv, Lymphknotenbefall bzw. Fernmetastasen dar. Von den bisher eingesetzten Radiopharmaka haben sich die radioaktiv markierten PSMA-Liganden (z. B. Ga-68 PSMA) durchgesetzt. Es gibt auch mittlerweile gute Therapieansätze mit PSMA Liganden (z. B. Lu-177 PSMA) bei metastasierter Erkrankung.

Summary

Prostate cancer is the most frequent cancer type in men in industrialized countries. In case of biochemical recurrent disease of prostate cancer is molecular imaging with PET-CT or PET-MRI a very promising modality for the detection of local recurrence, lymph node involvement or distant metastasis. Of the so far implemented radiopharmaceuticals the radioactive labeled PSMA ligands (i. e. Ga-68 PSMA) have prevailed. There are also in the meanwhile treatment approaches with PSMA ligands (i. e. Lu-177 PSMA) in case of metastatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Statistik Austria. Prostata. 2018. http://www.statistik.at/web_de/statistiken/menschen_und_gesellschaft/gesundheit/krebserkrankungen/prostata/index.html. Zugegriffen: 20. Juli 2018.

    Google Scholar 

  2. Eiber M, Röthke MC. Diagnose und Ausbereitungsdiagnostik des Prostatakarzinoms. Forum Fam Plan West Hemisph. 2016;31:115–20.

    Google Scholar 

  3. Kranzbühler B, Nagel H, Becker AS, et al. Clinical performance of 68 Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2018;45:20–30.

    Article  Google Scholar 

  4. Thomas L, Balmus C, Ahmadzadehfar H, et al. Assessment of bone metastases in patients with prostate cancer-a comparison between (99m)Tc-bone-scintigraphy and [(68)Ga]Ga-PSMA PET/CT. Pharmaceuticals (Basel). 2017;10:68–78.

    Article  Google Scholar 

  5. Abikhzer G, Srour S, Fried G, et al. Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer. Nucl Med Commun. 2016;37:1160–8.

    Article  CAS  Google Scholar 

  6. DKG, Deutsche Krebshilfe, AWMF, Hrsg. S3 Leitlinie. 2016. https://leitlinienprogramm-onkologie.de/uploads/tx_sbdownloader/LL_Prostata_Langversion_4.0.pdf. Zugegriffen: 20. Juli 2018.

    Google Scholar 

  7. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 69Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–74.

    Article  Google Scholar 

  8. Grubmüller B, Baum RP, Capasso E, et al. 64Cu-PSMA-617PET/CT imaging of prostate adenocarcinoma: first in-human studies. Cancer Biother Radiopharm. 2016; https://doi.org/10.1089/cbr.2015.1964.

    Article  PubMed  Google Scholar 

  9. Khawar A, Eppard E, Sinnes JP, et al. [44Sc]Sc-PSMA-617 biodistribution and dosimetry in patients with metastatic castration-resistant prostate carcinoma. Clin Nucl Med. 2018;43:323–30.

    Article  Google Scholar 

  10. Virgolini I, Decristoforo C, Haug A, et al. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:471–95.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Nuklearmedizin mit PET-Zentrum, Wilhelminenspital, Montleartstraße 37, 1160, Wien, Österreich

    Siroos Mirzaei MBA & Peter Knoll

  2. Institut für Radiologie und Nuklearmedizin, Hanusch-Krankenhaus, Wien, Österreich

    Shahin Zandieh

Authors
  1. Siroos Mirzaei MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Knoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shahin Zandieh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Siroos Mirzaei MBA.

Ethics declarations

Interessenkonflikt

S. Mirzaei, P. Knoll und S. Zandieh geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mirzaei, S., Knoll, P. & Zandieh, S. Die Rolle der molekularen Bildgebung (PET-CT) in der Diagnostik und Therapie des Prostatakarzinoms. Wien Med Wochenschr 169, 12–14 (2019). https://doi.org/10.1007/s10354-018-0668-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10354-018-0668-5

Schlüsselwörter

Keywords

Search

Navigation